NCT06794827 Early-access Avacopan in Real-world ANCA-associated Vasculitis
| NCT ID | NCT06794827 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leiden University Medical Center |
| Condition | ANCA Associated Vasculitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-11-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.
Eligibility Criteria
Inclusion Criteria: * Established diagnosis of GPA or MPA * Treatment (initiation) with avacopan * Informed consent for use of medical data Exclusion Criteria: * If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment * If a subject is below 16 years old
Contact & Investigator
Y.K. Onno Teng
PRINCIPAL INVESTIGATOR
Leiden University Medical Center
Frequently Asked Questions
Who can join the NCT06794827 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying ANCA Associated Vasculitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06794827 currently recruiting?
Yes, NCT06794827 is actively recruiting participants. Contact the research team at y.k.o.teng@Lumc.nl for enrollment information.
Where is the NCT06794827 trial being conducted?
This trial is being conducted at Leiden, Netherlands.
Who is sponsoring the NCT06794827 clinical trial?
NCT06794827 is sponsored by Leiden University Medical Center. The principal investigator is Y.K. Onno Teng at Leiden University Medical Center. The trial plans to enroll 100 participants.